Article Text

PDF
Extended report
Circulating cytokines in active polymyalgia rheumatica
  1. L Alvarez-Rodríguez1,
  2. M Lopez-Hoyos2,
  3. C Mata3,
  4. M Jose Marin2,
  5. J Calvo-Alen3,
  6. R Blanco1,
  7. E Aurrecoechea3,
  8. M Ruiz-Soto1,
  9. V M Martínez-Taboada1
  1. 1
    Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Facultad de Medicina, Universidad de Cantabria, Santander, Spain
  2. 2
    Servicio de Inmunología, Hospital Universitario Marqués de Valdecilla, Facultad de Medicina, Universidad de Cantabria, Santander, Spain
  3. 3
    Fundación Marqués de Valdecilla-IFIMAV, Sección de Reumatología, Hospital de Sierrallana, Torrelavega, Cantabria, Spain
  1. Correspondence to Dr V M Martínez-Taboada, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Facultad de Medicina, Universidad de Cantabria, Avda Valdecilla s/n 39008, Santander, Spain; vmartinezt{at}medynet.com

Abstract

Objective: To characterise the circulating cytokine profile and the cellular source of circulating cytokines in polymyalgia rheumatica (PMR).

Methods: The study included 34 patients with active untreated PMR and 17 age-matched healthy controls (HC). Circulating cytokines were measured by cytometric bead array and ELISA. Intracellular cytokines were assessed in CD3+ and CD14+ cells by flow cytometry. Cytokines in cell culture supernatants were also determined after polyclonal stimulation of patients’ peripheral blood mononuclear cells.

Results: Circulating levels of interleukin-6 (IL6) were significantly higher in subjects with active PMR than in HC. Corticosteroid (CS) treatment was followed by a decrease in the level of IL6. Intracellular cytokine staining showed that circulating monocytes did not produce higher amounts of proinflammatory cytokines in patients with PMR than in HC. There was a discordance between serum levels and cytokine-producing monocyte and T cells, and it was not possible to demonstrate a Th1 bias in the peripheral compartment.

Conclusions: Active PMR is characterised by increased serum levels of IL6, but not of other proinflammatory cytokines, that are rapidly suppressed by CS treatment. As circulating monocytes do not show increased production of proinflammatory cytokines, IL6 may be mainly produced in the inflamed tissue. A study of the circulating cytokine profile and its cellular source may provide a clue to new therapeutic options.

Statistics from Altmetric.com

Footnotes

  • Funding This work was supported by grants from Fondo de Investigación Sanitaria (05/0475), Fundación Marqués de Valdecilla and Fundación Mutua Madrileña. LA-R was supported by a grant for Research Aid from Wyeth Pharma (Spain).

  • Competing interests None.

  • Ethics approval All the patients and controls gave signed informed consent and the study was approved by the regional ethics committee.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.